Scarica l'app Stockscreener
1.035
1.47%
0.015
Dopo l'orario di chiusura:
1.04
0.005
+0.48%
Precedente Chiudi:
$1.02
Aprire:
$1.03
Volume 24 ore:
45,702
Relative Volume:
0.48
Capitalizzazione di mercato:
$20.16M
Reddito:
$411.00K
Utile/perdita netta:
$-4.85M
Rapporto P/E:
-2.3523
EPS:
-0.44
Flusso di cassa netto:
$-4.88M
1 W Prestazione:
+6.70%
1M Prestazione:
-11.54%
6M Prestazione:
-50.24%
1 anno Prestazione:
-72.76%
Intervallo 1D:
$1.02
$1.05
Intervallo di 1 settimana:
$0.97
$1.12
Portata 52W:
$0.9452
$4.44
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Nome
Lexaria Bioscience Corp
Settore
Industria
Telefono
250-765-6424
Indirizzo
100 - 740 MCCURDY ROAD, KELOWNA
Confronta LEXX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
1.035 | 18.97M | 411.00K | -4.85M | -4.88M | -0.44 |
|
ONC
Beone Medicines Ltd Adr
|
246.68 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.09 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 40.37M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.39 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
77.49 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
Lexaria Bioscience Corp Borsa (LEXX) Ultime notizie
Lexaria Bioscience Corp (NASDAQ: LEXX) Is Down -15.79% Since Its Low, And It’s Only Getting Started. - Stocksregister
Lexaria advances drug delivery tech with PharmaCO By Investing.com - Investing.com Nigeria
Raymond James Financial Inc. Makes New Investment in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria (LEXX) Advances Collaborative Pharmaceutical Research | - GuruFocus
Lexaria Advances Collaboration with Pharma Partner on Drug Delivery Technology - TipRanks
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company - marketscreener.com
Lexaria Provides Update on Material Transfer Agreement with Phar - GuruFocus
Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Bioscience announces $2M registered direct offering; shares slip 19% - MSN
Lexaria Bioscience stock hits 52-week low at $1.14 By Investing.com - Investing.com India
Lexaria Bioscience stock hits 52-week low at $1.14 - Investing.com Australia
Lexaria Announces Closing of $2 Million Registered Direct Offeri - GuruFocus
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock - Yahoo Finance
Lexaria Bioscience Secures $2 Million in Direct Stock Offering - TipRanks
Lexaria Secures $2M Strategic Investment in Clean Direct Offering Amid Market Turbulence - Stock Titan
Market Watch Highlights: Lexaria Bioscience Corp (LEXX) Ends on an Downturn Note at 1.35 - DWinneX
Lexaria Bioscience Corp (LEXX) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
What is Zacks Small Cap’s Estimate for LEXX FY2025 Earnings? - Defense World
Lexaria Bioscience (LEXX) Announces $2M Direct Offering | LEXX S - GuruFocus
Lexaria Bioscience Secures $2 Million in Registered Direct Stock Offering - citybuzz -
Lexaria Announces $2 Million Registered Direct Offering of Commo - GuruFocus
Lexaria Bioscience secures $2 million in direct offering By Investing.com - Investing.com South Africa
Lexaria Bioscience secures $2 million in direct offering - Investing.com
Lexaria Announces $2 Million Registered Direct Offering of Common Stock - TradingView
Lexaria Lands $2M Strategic Investment: Institutional Investor Backs Biotech at $1.00 Per Share - Stock Titan
Lexaria Bioscience (OTCMKTS:LXRP) versus U.S. Gold (NASDAQ:USAU) Critical Comparison - Defense World
LEXX: Second Quarter Results - Yahoo Finance
Lexaria Bioscience (LEXX) Advances in GLP-1 Technology Amid Indu - GuruFocus
Recent GLP-1-Industry Developments Highlight the Promise of Lexa - GuruFocus
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology | LEXX Stock News - GuruFocus
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology - TradingView
Revolutionary Technology Could Solve GLP-1's Biggest Challenge: 64% Patient Dropout Rate - Stock Titan
Lexaria Bioscience earnings beat by $0.02, revenue topped estimates - Investing.com
Lexaria Corp. Announces Oil Discovery at PPF-12-7 well in Belmont Lake - marketscreener.com
Lifezone Metals (NYSE:LZM) vs. Lexaria Bioscience (OTCMKTS:LXRP) Financial Review - Defense World
Lexaria Bioscience Corp reports results for the quarter ended February 28Earnings Summary - TradingView
Lexaria Bioscience Corp. SEC 10-Q Report - TradingView
60,640 Shares in Lexaria Bioscience Corp. (NASDAQ:LEXX) Acquired by Raymond James Financial Inc. - Defense World
Lexaria gets ethics board okay for oral GLP-1 study - MSN
We Think Lexaria Bioscience (NASDAQ:LEXX) Needs To Drive Business Growth Carefully - Yahoo
HighTower Advisors LLC Boosts Holdings in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World
Lexaria Completes Enrollment for Pioneering Drug Delivery Study - TipRanks
Lexaria completes enrollment for diabetes drug study - Investing.com
Lexaria completes enrollment for diabetes drug study By Investing.com - Investing.com UK
Lexaria's GLP-1 Study Hits Major Milestone with 20% Higher Patient Enrollment - Stock Titan
Lexaria begins human trial for oral diabetes treatment - Investing.com India
Lexaria Bioscience Corp Azioni (LEXX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):